People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Other Health Care, Medical Devices, Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Eargo, Inc. | — | Other Health Care | Series C | $187.4M | $1.8B | 2018 |
| Htg Molecular Diagnostics, Inc | — | Medical Devices | Series B | $65.3M | $110.3M | 2014 |
| Ceterix Orthopaedics, Inc. | — | Other Health Care | Series B | $54.4M | $510.5M | 2012 |
| Light Sciences Oncology Inc | — | Biotechnology | Series B | $45.0M | $80.4M | 2011 |
| Otonomy, Inc. | — | Biotechnology | Series B | $44.8M | $961.1M | 2010 |
| OncXerna Therapeutics, Ltd. | — | Biotechnology | Series B | $30.0M | $590.7M | 2022 |
| Addition Therapeutics, Inc. | — | Biotechnology | Series B | $28.0M | $107.3M | 2025 |
| Altheos, Inc. | — | Other | Series B | $23.1M | $275.1M | 2011 |
| M2 Group Holdings Inc | — | Other Health Care | Series A | $6.0M | $121.1M | 2009 |
Peter Bisgaard at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Bisgaard on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Wende Hutton | 1 | 16 |
| Kirk Nielsen | 1 | 13 |
| Joshua Makower | 1 | 10 |
| Juliet Bakker | 1 | 9 |
| Dennis Langer | 1 | 9 |
| Jeffrey Harris | 1 | 9 |
| Simeon George | 1 | 8 |
| David Weber | 1 | 8 |
| Kevin Sidow | 1 | 7 |
| Jay Lichter | 1 | 7 |
| Brian Dovey | 1 | 7 |
| David Wu | 1 | 7 |
| Peter McNerney | 1 | 6 |
| Rob Hopfner | 1 | 6 |
| Douglas Downs | 1 | 6 |
| Geoff Pardo | 1 | 6 |
| Terry Gould | 1 | 6 |
| Court Turner | 1 | 6 |
| Heather Preston | 1 | 6 |
| Harry George | 1 | 6 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.